Status:
COMPLETED
A Clinical Investigation to Assess the Performance of a Polyurethane Condom Versus a Latex Condom in Healthy Monogamous Couples
Lead Sponsor:
Reckitt Benckiser Healthcare (UK) Limited
Collaborating Sponsors:
Novotech (Australia) Pty Limited
Conditions:
Control of Pregnancy
Prevention of Sexually Transmitted Infections
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
This investigation is designed to evaluate the performance rate of a polyurethane (PU) condom versus a standard natural rubber latex (NRL) condom.
Detailed Description
In this clinical investigation, a new PU male condom (test condom) will be evaluated against a marketed NRL male condom (reference condom). This clinical investigation will also evaluate the in-use to...
Eligibility Criteria
Inclusion
- Main
- A male and a female subject aged: 18 - 60 years inclusive.
- All subjects must be generally healthy and in a mutually monogamous heterosexual relationship - current relationship ≥ 3 months.
- All couples must be sexually active and agree to have penile-vaginal intercourse with a frequency sufficient to meet protocol requirements (a minimum of 5 coital acts over 4 weeks).
- The female partner should already be on an established highly effective form of non-barrier contraception, unless post-menopausal.
- Couples must agree not to use drugs or non-investigational devices that can affect sexual performance.
- Main
Exclusion
- Either partner is or becomes aware of an allergy or sensitivity to the ingredients of the test products, including the test or reference condoms.
- Either partner has a pre-existing skin condition (severe eczema/ psoriasis) or systemic allergic reactions or as confirmed by the subject and physical examination.
- Either partner that needs to use condoms for a specific sexually transmitted infection (STI) protection e.g. discordance for Human Immunodeficiency Virus (HIV) or herpes.
- Subjects that have previous or planned genital surgery, that in the opinion of the Investigator would consider the subject unsuitable to participate in the clinical investigation e.g. laser for abnormal smear.
- Male partners that have known erectile or ejaculatory dysfunction.
- A female partner that has been diagnosed with or treated for vaginal complaints (including vaginal dryness) in the previous 3 months which, in the opinion of the investigator, deems the partner unsuitable for the investigation.
- Any subject who has clinical symptoms or signs of a sexually transmitted diseases (STD) or HIV/ AIDS or has a previous history of high-risk behaviour as judged by the investigator.
- Female partner using medication which in the investigator's opinion would affect vaginal mucosal secretion, such as Chlorpheniramine at any time in the 14 days (or 5 half-lives of the drug, whichever is longer) before first condom use.
- A male partner with abnormal penile anatomy that would, in the opinion of the investigator, affect the ability to keep the condom in place during intercourse.
- Either partner intends to continue to use antihistamines, anti-inflammatory drugs or pain killers for the duration of the investigation.
Key Trial Info
Start Date :
February 9 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 5 2021
Estimated Enrollment :
470 Patients enrolled
Trial Details
Trial ID
NCT04134039
Start Date
February 9 2021
End Date
July 5 2021
Last Update
September 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King Chulalongkorn Memorial Hospital
Bangkok, Thailand